What's Happen Under the Calcification Process in Pseudoxanthoma Elasticum (GOCAPXE)
Primary Purpose
Pseudoxanthoma Elasticum
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
PET scan 18-FDG and 18-NAF
Sponsored by
About this trial
This is an interventional basic science trial for Pseudoxanthoma Elasticum focused on measuring Low Grade Chronic vascular and skin Inflammation, Molecular vascular and skin Calcification, Calcium Score
Eligibility Criteria
Inclusion Criteria:
- PXE patient diagnosed according the international criteria
- Informed consent obtained
- Patient affiliated to Health care system
Exclusion criteria included inability or unwillingness to provide informed consent. Also, women of childbearing age not receiving contraception, pregnant women, nursing women, diabetic patients, patients with osteopenia, inflammatory or autoimmune systemic disease, high blood glucose concentrations (> 11 mmol/L) because of the competition between glucose and 18F-FDG for cellular entry.
Sites / Locations
- University Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
PXE Patient
Arm Description
positron emission tomography scanner (PET scan) 18-FDG and 18-NAF: conventionnal use.
Outcomes
Primary Outcome Measures
Vascular Inflammation
Measurement 18F-FDG TBRs of patients with PXE; and the comparison of 18F-NaF femoral arteries' TBRs with popliteal artery's TBRs of patients with PXE (at 30 min and 90min post injection).
Molecular Calcification
Measurement 18F-NaF femoral arteries' TBRs with popliteal artery's TBRs of patients with PXE
Secondary Outcome Measures
Full Information
NCT ID
NCT03070860
First Posted
June 13, 2016
Last Updated
June 27, 2018
Sponsor
University Hospital, Angers
1. Study Identification
Unique Protocol Identification Number
NCT03070860
Brief Title
What's Happen Under the Calcification Process in Pseudoxanthoma Elasticum
Acronym
GOCAPXE
Official Title
Glucidic Metabolism, Ossification and Arterial Calcification During PseudoXanthoma Elasticum (PXE)
Study Type
Interventional
2. Study Status
Record Verification Date
June 2018
Overall Recruitment Status
Completed
Study Start Date
November 2016 (Actual)
Primary Completion Date
December 2017 (Actual)
Study Completion Date
December 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Angers
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The investigators hypothesize is that in PXE patients, low grade chronic inflammation could preceed the molecular and the clinical calcification process.
Detailed Description
Pseudoxanthoma elasticum (PXE; OMIM 264800), is an autosomal recessive metabolic disorder characterized by the fragmentation and progressive calcification of elastic fibers(elastorrhexis) in connective tissue in the skin, Bruch's membrane of the retina and the vascular system. PXE is caused by mutations in the ABCC6 (ATP-binding cassette subfamily C member 6) gene, located on the short arm of chromosome 16, encoding a transmembrane ATP binding anion transporter normally expressed in the liver and the kidney. The pathophysiology of PXE, particularly the mechanism of ectopic mineralization, remains largely unknown. PXE is currently an intractable disease, associated with considerable morbidity and occasional mortality due to cardiovascular complications. The major symptoms of the disease are characterized by unaesthetic skin folds, central blindness and cardiovascular complication with an early and severe peripheral arterial disease (PAD) and complication at younger age than the normal population. Unfortunately, histological studies are limited by the availability of arterial tissue from patients but it has been showed calcium deposition in the media layer of the large (i.e. aorta, carotids and femoral) and medium sized vessels (i.e. radial and ankle arteries) (ref). However, the underlying pathophysiology for arterial calcification in PXE remains incompletely defined, and there are currently no effective medical treatments capable of altering its course.
No longitudinal study has been performed to explain the calcification process in PXE. As PXE is a systemic metabolic disease, low grade inflammation could be the trigger of a deregulated inflammation resolution process resulted in calcification. Thus, alternative techniques are therefore required to investigate the pathogenesis and progression of this condition.
Positron emission tomography (PET) combined with computed tomography (CT) is a noninvasive imaging technique that allows the identification and quantification of specific biochemical processes within small anatomic structures, such as vascular wall. Furthermore, 2 common PET tracers target calcification and inflammation, which are believed to play a key role in the development of the disease. 18F Flurodeoxyglucose (18F-FDG) is a glucose analogue that is taken up into cells by glucose transport proteins and enters the glycolytic metabolic pathway. After the initial hexokinase step, 18F-FDG-6-phosphate cannot be metabolized further and becomes trapped within cells that have high metabolic requirements, such as macrophages. PET imaging with the use of 18F-FDG has become an established means of quantifying vascular inflammation in both the aorta and carotid arteries, correlating with plaque macrophage burden and symptomatic status. 18F-Sodium fluoride (18FNaF) is an alternative PET tracer that is directly incorporated into exposed bone crystal (hydroxyapatite) via an exchange mechanism with hydroxyl groups. It is therefore thought to detect areas of novel calcification and regions of calcium remodeling and is used clinically for the detection of primary osteoblastic tumors and bone metastases. More recently, studies have described 18F-NaF uptake as a marker of calcification within atherosclerotic plaque. More recently, the calcifying process was examined in 4 PXE patients using 18NaF PET/CT showing in the femoral arteries, increased arterial wall 18NaF signal at levels similar to those for cortical bone. However, the mechanism responsible for the increased osteoblastic activity leading to arterial wall calcification in PXE remains unknown.
.
In this study, the investigators investigated 18F-NaF and 18F-FDG uptake in the arterial wall and skin of patients with PXE with 3 major aims: :
Does low grade inflammation in vascular wall and skin exist in PXE patient and a specificity site might exist?
Does low grade inflammation in vascular wall and skin quantified by 18F-FDG preceed the molecular calcification process quantified by 18F-NaF?
Does low grade inflammation and bone turn over correlate conversely to calcium score?
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pseudoxanthoma Elasticum
Keywords
Low Grade Chronic vascular and skin Inflammation, Molecular vascular and skin Calcification, Calcium Score
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
23 (Actual)
8. Arms, Groups, and Interventions
Arm Title
PXE Patient
Arm Type
Experimental
Arm Description
positron emission tomography scanner (PET scan) 18-FDG and 18-NAF: conventionnal use.
Intervention Type
Radiation
Intervention Name(s)
PET scan 18-FDG and 18-NAF
Other Intervention Name(s)
positron emission tomography
Intervention Description
Positron emission tomography (PET) is a medical imaging test performed in a nuclear medicine department.
PET scan is performed by IV injection of a mildly radioactive tracer (NAF and FDG).
Primary Outcome Measure Information:
Title
Vascular Inflammation
Description
Measurement 18F-FDG TBRs of patients with PXE; and the comparison of 18F-NaF femoral arteries' TBRs with popliteal artery's TBRs of patients with PXE (at 30 min and 90min post injection).
Time Frame
90min post injection : 1 time
Title
Molecular Calcification
Description
Measurement 18F-NaF femoral arteries' TBRs with popliteal artery's TBRs of patients with PXE
Time Frame
90min post injection : 1 time
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
PXE patient diagnosed according the international criteria
Informed consent obtained
Patient affiliated to Health care system
Exclusion criteria included inability or unwillingness to provide informed consent. Also, women of childbearing age not receiving contraception, pregnant women, nursing women, diabetic patients, patients with osteopenia, inflammatory or autoimmune systemic disease, high blood glucose concentrations (> 11 mmol/L) because of the competition between glucose and 18F-FDG for cellular entry.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Loukman OMARJEE, MD,MSc
Organizational Affiliation
University Hospital, Angers
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital
City
Angers
ZIP/Postal Code
49933
Country
France
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
What's Happen Under the Calcification Process in Pseudoxanthoma Elasticum
We'll reach out to this number within 24 hrs